Type 2 inflammatory asthma Respiratory
Conditions
Interventions
This is an observational study, which means it will not be testing a new drug or treatment. Instead, the study will carefully study people with asthma to better understand what is happening in their l
Sponsors
Asthma + Lung UK
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged =18 years old with GINA-defined moderate-to-severe asthma. 2. Taking a medium to high dose of ICS/LABA OR high dose ICS with another second line controller (BDP equivalent dose of =800µg) of step 4/5 GINA therapy. 3. Established diagnosis of persistent asthma =6 months according to GINA guidelines. 4. Ability to give informed consent. 5. Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant’s wellbeing. 6. Able to understand the study procedures and the risks involved. 7. Good physical and mental status, determined on the basis of the medical history and a general clinical examination at screening.
Exclusion criteria
Exclusion criteria: 1. Patients who are taking biologics for asthma. 2. Patients who are on maintenance oral corticosteroids. 3. Patients who have required a course of oral corticosteroids in the past month. 4. Any other respiratory diseases such as COPD and moderate to severe bronchiectasis which in the opinion of the investigator are clinically significant and may have an impact on the study outcomes. 5. Any disorder that is not stable in the opinion of the Investigator. 6. Patients unable or unwilling to consent. 7. Anyone who has had a recent chest infection or asthma exacerbation (within the past 4 weeks), as this may temporarily alter neutrophil levels in the sputum. 8. People currently taking part in another clinical trial involving investigational medicines or who have received such medicines within the past 3 months. 9. Individuals with severe comorbidities (such as uncontrolled heart disease, active cancer, or significant immunosuppression) where participation may pose additional risk.
Countries
Scotland, United Kingdom
Contacts
Public ContactRory Chan
Outcome results
None listed